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Abstract 
 
Epigenetics is the study of heritable traits that are not caused by alterations to 
DNA. An example of such a mechanism is histone methylation, specifically 
histone H3 lysine 4 (H3K4). Histones are proteins that wrap and package DNA 
into nucleosomes. Modifications to a histone’s chemistry can up or down regulate 
specific gene expression programs through changes in nucleosome positioning. 
Human mixed lineage leukemia protein-1 (MLL1) is a member of the SET1 
family of H3K4 methyltransferases. Previous studies in the Cosgrove lab have 
shown that an interaction between two protein sub-complexes, MLL1 and WRAD 
(WDR5, RbBP5, Ash2L, DPY30), leads to dimethylation. H3K4 dimethylation 
plays an important role in normal development and hematopoiesis in humans. 
Disruption of core complex formation from amino acid point mutations can lead 
to a decrease, or even complete loss, of dimethylation. 
 
Kabuki Syndrome (KS) is a multiple malformation disorder that was recently 
discovered to be associated with mutations in mixed lineage leukemia protein-2 
(MLL2), a paralog of MLL1 and member of the SET1 family of proteins. Using 
the experimental model established with MLL1, tests were conducted that 
determined the importance of a highly conserved arginine residue (R). In MLL1, 
this R3765 (MLL2 R5340) was mutated into leucine, which revealed a severe loss 
of H3K4 dimethylation resulting from failure of MLL1 to interact with WDR5. 
Additional KS and non-KS (control) MLL1 mutations from MLL2 screens of 
patients were tested and suggested a correlation between changes in H3K4 
methylation and KS. 
 
Protein arginine deiminases (PADs) are enzymes that post translationally modify 
arginine into citrulline, a non-standard amino acid. Previous work with KS led us 
to hypothesize a possible regulation system of PAD and SET1 family proteins. 
While PAD is able to disrupt complex formation by changing R3765 into 
citrulline, thereby down-regulating dimethylation, mutations in SET1 family 
proteins can elevate dimethylation when in complex with WRAD. Thereby 
creating an “on” and “off” system of protein interaction. Previous work in the 
Cosgrove lab showed preferential interaction between PAD2 and MLL1. Initial 
assays were conducted and optimized that supported this hypothesis, as well as 
laying the ground work for future experimentation. 
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Executive Summary 
 
Mixed lineage leukemia protein-1 (MLL1) and WRAD (WDR5, RbBP5, Ash2L, 
DPY30) are two parts of a protein core complex called MWRAD. Separately, 
MLL1 and WRAD can only monomethylate, which means they add one methyl 
(CH3) group onto a histone called histone H3 lysine 4 (H3K4). When in complex, 
MWRAD is able to dimethylate or add two methyl groups. Histones are proteins 
that consolidate DNA by wrapping them up. Without histones the DNA would be 
very long and each human cell would contain 1.8 meters of DNA, as opposed to 
90 micrometers, a ten-thousand fold difference. Usually genes and traits are 
thought to be passed down through each individual’s genetic DNA code. 
However, there exists a new field of study called epigenetics, whereby inherited 
traits are passed down through modifications outside of DNA, an example being 
histone methylation. 
 
The Cosgrove lab has worked extensively with this model system and have 
discovered a highly conserved six amino acid motif in MLL1 called the Win 
motif that acts as a bridge with WDR5. Mutations in this region lead to a 
disruption of complex formation between MLL1 and WRAD, thereby decreasing 
the amount of H3K4 dimethylation. This can be thought as a lock and key 
mechanism where the Win motif is inserted into a WRAD binding site. 
 
My work has primarily revolved around that region of MLL1 and understanding 
the mechanisms behind the regulation of this MLL1 core complex. During my 
three years, I was tasked with two separate projects. The first focused on Kabuki 
Syndrome (KS), a congenital disorder that has been linked with MLL2. MLL1 
and MLL2 are part of a family of proteins, so they are very similar in nature. 
Therefore, it was hypothesized that we could test KS and non-KS (controls) 
mutations found in MLL2 using MLL1. Results showed a correlation between 
mutations in KS patients and a loss of dimethylation. 
 
After successfully publishing a paper with members of the Cosgrove lab, I was 
assigned to a second project dealing with protein arginine deiminase (PAD), an 
enzyme that modifies an amino acid called arginine. Prior work showed a relation 
between PAD2 and MLL1 leading us to believe that there could exist a regulation 
mechanism for H3K4 dimethylation. Essentially PAD2 would hypothetically 
lower dimethylation in the case that there is an overexpression of dimethylation, 
as the human body maintains a delicate homeostasis by keeping gene expression 
in a specific range. Furthermore, detrimental mutations to PAD2 could be a cause 
for KS, as it would change one of the highly conserved amino acids in the Win 
motif. Unfortunately I was only able to lay the ground works for this project due 
to time constraints. Future work will hopefully be able to verify the data that was 
obtained. 
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Chapter I 
Introduction 
 
 
 
 
The Human Mixed Lineage Leukemia Protein-1 (MLL1) Core Complex 
Nucleosomes are fundamental units in genetic regulation and they consist of DNA 
wrapped around eight histone proteins. Changes in the position of a nucleosome 
can cause varying levels of over-expression or suppression of genes. Chromatin, 
containing multiple nucleosomes, can be transcriptionally activated or deactivated 
with histone lysine methylation, a crucial epigenetic system
1
. Epigenetics is the 
study of gene expression programs that does not originate from alterations in the 
DNA. Post-translational modifications of histones can reveal or cover binding 
sites for proteins involved in gene expression. Mixed lineage leukemia protein -1, 
MLL1, named as such due to mutations frequently leading to acute leukemia, is 
one of six members in the SET1 family of H3K4 methyltransferases with the 
other five being: MLL2, MLL3, MLL4, SET1a, and SET1b
1
. The SET1 family is 
one of many SET domain proteins that exist based on similarities in sequence and 
structural features. Alone, the SET1 family can only participate in the slow 
monomethylation of H3K4
1
. However, dimethylation is possible in the presence 
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of the WDR5, RbBP5, ASH2L, and DPY-30 (WRAD) complex
1
. WRAD acts 
similarly to MLL1 and can monomethylate H3K4
1
. MWRAD, in contrast, shows 
a ~600 fold increase in H3K4 dimethylation
1
. Interestingly, mono- and 
dimethylation occur sequentially at two unique sites in the MWRAD complex
1
. 
Previous and current work in Dr. Michael Cosgrove’s lab focuses on 
understanding the structure and function of MWRAD. H3K4 dimethylation is 
important in the normal development and hematopoiesis of humans
1
. Under wild-
type conditions, the MLL1 core complex is capable of H3K4 dimethylation, but 
point mutations in the amino acid sequence altering the amount of dimethylation 
have been linked with a variety of human diseases
1
. If the core complex is unable 
to form, then there will only be monomethylation
1
. 
Post Translational Modifications in Kabuki Syndrome 
Kabuki Syndrome (OMIM 147920) is a human multiple malformation disorder 
categorized by intellectual disability, facial abnormalities, heart problems, hearing 
loss, growth deficiency, and short stature
2
. Due to the rare nature of this disease (1 
in 32,000 with only 400 reported cases), it was not until 1981 that two separate 
scientists, Norio Niikawa and Yoshikazu Kuroki, identified Kabuki Syndrome 
(KS)
2
. Named as such due to the similarities with Kabuki makeup, a type of 
Japanese theatre
2
. Since most reported incidences arose de novo, KS is suggested 
to be an autosomal dominant disorder or X-linked recessive
2
. Classification of KS 
is still not completely understood, as many of the conditions are shared with other 
diseases like Down Syndrome
2
. Currently, four of the five cardinal features must 
be met in order to make a KS diagnosis, including: facial appearance, skeletal 
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abnormalities, fetal finger pads, intellectual disability, and short stature
3
. Exome 
sequencing in the early-2000s, as well as large spectrum analysis of KS patients 
that followed were unable to pinpoint one shared gene at fault, however the 
majority of individuals tested had a mutation in MLL2
2,3
. Nine of ten patients in 
the initial screen had an altered MLL2 gene, while two thirds of a larger (n = 43) 
screen had mutations in MLL2
2
. Seventy two percent of a 110 KS family screen 
had adversely affected MLL2
3
. Though not all those diagnosed with KS had the 
MLL2 mutant, a possible explanation for those without MLL2 mutations could be 
incorrect identification, the existence of another related developmental disease, or 
mutations existing in the noncoding region
2
. Loss-of-function mutations in MLL2 
likely alters H3K4 methylation in KS and, as such, is believed to be linked to the 
problems in early human development for Kabuki Syndrome patients
2
. In 
addition, tests done on MLL2 knock out mouse models were lethal
3
. KS is one of 
many syndromes classified by developmental delay and disrupted histone 
methylation
3
. 
Significance of the WDR5 Interaction (Win) Motif  
The WD repeat protein-5 (WDR5) is a conserved component in SET1 family 
complexes that is shared across many different species
4
. It was discovered in 2008 
that there exists a bridge between MLL1 and WDR5 that assists in core complex 
formation
4
. The Win motif, a six amino acid residue sequence (GSARAE) is 
located in the N-SET region of MLL1 and contains a highly conserved arginine 
(R3765) that was shown to be bind in the pocket of WDR5
4
. R3765 exists in all 
members of the SET1 family and is important in the enzymatic activity of the 
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MWRAD complex
5
. Mutations in the Win motif could lead to a significant 
disruption in the dimethylation activity attributed to normal hematopoiesis and 
human growth
6
. 
Mutations Affecting Histone H3 Lysine 4 (H3K4) Methylation 
During the KS mutation screen, MLL2 arginine 5340 was found to be mutated 
into a leucine
2
. This amino acid position is homologous to MLL1 R3765 in the 
Win motif
4
. Due to the correlation between two previous research papers, it was 
hypothesized that by utilizing the established in vitro model system of MLL1, the 
effects of a mutation in MLL2 could be determined given the great amount of 
similarity between the two proteins. MLL1 is a paralog of MLL2, thereby 
presenting the opportunity to understand the effects of the KS MLL2 R5340 
mutationL. This change in amino acid to leucine leads to a loss of charge, shorter 
atomic structure, and increased hydrophobicity. In addition, a non-KS related 
residue R3746 was mutated into a histidine as a control mutation that should not 
impact H3K4 methylation. Other screened MLL2 mutations were tested by a 
graduate student in the research lab. The identification and understanding of 
Kabuki Syndrome point mutations will hopefully open doors for possible 
treatments or earlier diagnosis
7
. 
 Peptidylarginine Deiminase (PAD) and the Impact of Citrullination 
PAD enzymes catalyze the citrullination of arginine and have been implicated in 
diseases such as rheumatoid arthritis, breast cancer, and multiple sclerosis
8
. The 
conversion of the NH2
+
 group on arginine to a keto group on citrulline leads to a 
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loss of the positive charge. The mammalian PAD family of enzymes consist of 
PAD1, PAD2, PAD3, and PAD4
8
. Of the four, PAD2 is expressed in the skeletal 
muscle, brain, spleen, and secretory glands
8
. In order for these enzymes to 
function properly, they require calcium ions (Ca
2+
)
8
. It has been hypothesized that 
PAD could be used as a possible inhibitor to histone methyltransferases
9
. For 
example, while MLL1 and WRAD interaction leads to dimethylation, PAD could 
possibly disrupt the interaction if there was an overexpression of dimethylation. In 
this way, citrullination can be used to counter a gain-of-function genetic mutation. 
Given that histone methylation is an epigenetic modification that has been linked 
with cancer, enzymes that directly or indirectly inhibit methylation could act as 
drugs to counter uncontrolled cell growth
9
. Furthermore, this field of study has 
only just begun to scratch the surface, if an inhibitor with specificity towards a 
histone methyltransferase were created, then it could aid in the fight against 
cancer, as well as other diseases
9
. In the past, the belief was that histone 
methylation was a permanent genetic modification
10
. Prior work with MLL1 
R3765 indicated that a mutation on this amino acid could lead to a complete loss 
of dimethylation. It is hypothesized that an overexpression of PAD2 on this 
arginine could lead to a patient with Kabuki Syndrome. It was shown in previous 
experiments that PAD2 catalyzes citrullination of R3765 and R3771 in MLL1. 
While based on previous work, citrullination of R3765 will likely disrupt complex 
formation, it is unclear what functional consequences result from R3771 
citrullination. 
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 Research Project Overview 
The goal of work in my thesis was to understand how MLL1 core complex (Fig. 
1) formation is regulated by R3765 and R3771 in MLL1. 
 
Figure 1 
In order to better understand the impact of MLL1 missense mutations, an 
experimental model (Fig. 2) was used to compare complex formation and H3K4 
methylation with wild-type MLL1. 
 
Figure 2 
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Chapter II 
Materials and Methods 
 
 
 
 
Mutagenesis. Point mutations were made using a site directed mutagenesis 
kit (QuickChange II, Strategene) on truncated wild-type human MLL1 
containing amino acid residues 3745-3969 in a pGST vector to introduce 
R3746H, R3765L, and R3771T mutations. Plasmids were sequenced by 
the DNA Sequencing Core Facility at SUNY Upstate Medical University 
to verify the presence of the desired mutation and the absence of 
additional unintended mutations. Primers were purchased from Integrated 
DNA Technologies. 
 
Protein Expression/Purification. Wild-type and mutant MLL1, as well as 
full-length wild-type human WDR5, RbBP5, ASH2L, and DPY-30 were 
individually expressed in Escherichia coli (Rosetta II, Novagen) and 
purified using affinity chromatography, as previously described
4
. In 
addition, proteins were dialyzed for buffer exchange and further purified 
using a gel filtration column (Superdex, 200, GE Healthcare) with filtered 
20mM Tris (pH 7.5), 300mM NaCl, 1mM Tris(2-carboxyethyl)phosphine, 
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and 1µM ZnCl2. Fractions from each step were selectively chosen after 
using SDS-PAGE gels to confirm the protein by molecular weight and 
maximize purity. Lastly, purified proteins were concentrated, if necessary, 
using a centrifuge concentration tubes (Millipore, Minicon). 
 
SDS-PAGE. Polyacrylamide gel electrophoresis (PAGE) was utilized to 
determine concentrations and purity of protein samples, as well as 
separating experimental time course reactions into individual protein 
components. Sodium dodecyl sulfate (SDS), a detergent, denatures 
proteins by unfolding them to become linear, thereby assisting in sample 
analysis. Bands on the gel (BioRad, Mini Protein TGX) were compared to 
a Precision Plus Protein Standard (BioRad). Coomassie stained and 
destained images were captured using a Gel Doc (BioRad) and bands were 
quantified using Image Lab. 
 
Nanodrop Spectroscopy. Concentrations (mg/mL) of gel filtration purified 
proteins were determined with a Nandrop 2000c (Thermo Scientific) at 
280nm. Relative values were obtained using 2µL of protein. 
 
Bradford Assays. Accurate concentrations (mg/mL) of proteins were 
obtained through Bradford Assays compared with a standard curve plot. 
Absorbance at 280nm were used to standardize concentrations of proteins 
prior to experiments. 
10 
 
 
Methyltransferase Assays. In vitro experiments using the MLL1 core 
complex at 7µM were done over a time course to test for mono-, di-, and 
tri-methylation activity as previously described
4
. 250µM of S-Adenosyl 
Methionine (AdoMet), as well as 10µM of H3 (residues 1-20) peptide, 
were added to the MWRAD complex and incubated at 15°C for 24 hours. 
Aliquots were withdrawn at different time points and quenched using 
0.5% Triflouroacetic acid (TFA). Each sample was then diluted 1:5 using 
α-cyano-4-hydroxycinnamic acid, dried, and analyzed in reflectron mode 
on the SUNY ESF MALDI-TOF mass spectrometer (Bruker Autoflex III). 
Data obtained was the average of 100 shots/position at 5 different 
positions chosen at random for each sample. Relative methylation values 
were determined using mMass and plotted on a Microsft Excel spread 
sheet to compare amounts of methylation over time. 
Analytical Ultracentrifugation. Wild-type and mutant MLL1 were mixed 
with various stoichiometric concentrations of WDR5 to determine if 
binding was effected by a point mutation. 3mm two-sector charcoal filled 
Epon centerpieces with quartz windows were assembled and samples were 
loaded. The Beckman Coulter ProteomLab XL-A analytical 
ultracentrifuge with absorbance optics was run at 10°C and 50,000RPM 
using a 4 hole An-50 Ti rotor. The program scanned 0-min time intervals 
for 300 scans and the data was analyzed using the continuous distribution 
method c(s) in SEDFIT. 
11 
 
 
GST Pulldown Assays. Wild-type and mutant GST-MLL1 proteins were 
mixed with the WRAD complex to compare binding affinity of the MLL1 
core complex after citrullination with PAD2. The proteins, assay buffer 
(50mM Tris (pH 8.5), 0.2M NaCl, 5% Glycerol, and 10mM CaCl2), and 
PAD2 were incubated at room temperature with glutathione beads over 
several time points. Reactions were stagger started, so as to end at the 
same time. Buffer washes were conducted to eliminate non-GST-bound 
proteins. SDS-PAGE was used to separate proteins on a gel and determine 
if WRAD successfully bound to GST-MLL1 in the presence of PAD2 
over time. 
 
Western Blotting. Novex NuPAGE gels were used to prepare 
electrophoresis samples. However, instead of coomassie staining, bands 
were transferred to a nitrocellulose membrane using electroblotting and 
20x NuPAGE transfer buffer. The membrane was then verified using 
Poncea S stain and the antibody was added. Lastly, the membrane was 
probed using an antibody that detects the citrullinated MLL1 protein. 
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Chapter III 
Results 
 
 
 
 
 Expression and Purification of MLL1 Mutants 
Human MLL1 3745-3969 mutants R3765L, R3746H, and R3771T were 
expressed by inducing at OD600 1.0 using Isopropyl β-D-1 thiogalactopyranoside 
(IPTG), which is a molecule that promotes transcription of the lac operon
4
. 
Verification of induction can been seen on the left (Fig. 3) with an SDS-PAGE 
gel.  
 
 
Figure 3 shows: 
Lane 1 = BioRad Standard Ladder (50kDa) 
Lane 2 = Uninduced MLL1-GST Protein 
Lane 3 = Induced MLL1-GST Protein 
The induced lane shows a significant increase in 
band intensity of protein between lane 2 and lane 
3, which confirms induction. 
 
             
                   Figure 3 
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Harvested pellets were lysed through as microfluidizer with an EDTA Free 
Protease Inhibitor Cocktail Tablet to avoid protein degradation. Purification of 
MLL1 mutants proceeded through a GST affinity chromatography, dialysis for 
buffer exchange, second GST affinity chromatography run, and finally gel 
filtration chromatography. At the end of each column run, sample tubes were 
chosen based off UV 280nm elution peaks when MLL1 came off the beads. These 
tubes, as well as the input and flow through, were displayed on a SDS-PAGE gel 
to analyze intensity of bands correlating to amount of protein and presence of 
contaminants. Sample aliquots of protein were saved throughout the process of 
purification for different experiments and stored at -80°C. GST fusion proteins 
after GST run 1 were used for GST pulldown assays, cleaved GST run 2 proteins 
were used for methylation assays, and gel filtration MLL1 was used for binding 
assays using sedimentation velocity analytical ultracentrifugation. Band intensity 
shown after gel filtration, though high in purity, were noticeably weaker and a 
loss of protein was seen each time for all mutants and wild-type MLL1 proteins. 
Destained coomassie gels can be seen below (Fig. 4, Fig. 5, Fig. 6) correlating to 
GST1, GST2, and gel filtration. 
 
Figure 4 (missing ladder) shows: 
Lane 1 = Input 
Lane 2 = Flowthrough 
Lane 3 – 9 = Select MLL1 
Protein Tubes 
 
                               Figure 4 
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Figure 5 shows: 
Lane 1 = BioRad Standard 
Ladder (25kDa) 
Lane 2 = Dialysis Input 
Lane 3 = Dialysis Output 
Lane 4 – 15 = Select MLL1 
Protein Tubes 
 
                                 Figure 5 
 
 
 
Figure 6 shows: 
Lane 1 = BioRad Standard Ladder (25kDa) 
Lane 2 = Non-Concentrated Gel Filtration MLL1 
Protein 
Lane 3 = Concentrated Gel Filtration MLL Protein 
 
 
 
              Figure 6 
 MLL1 R3765L – Disruption of Complex Formation 
Hypothesis: If the R3765L missense mutation in MLL1 causes loss-of-function 
due to changes in physical properties of the amino acid from an arginine to a 
15 
 
leucine, then this would be indicative of R5340L doing the same in MLL2 due to 
MLL1 and MLL2 being paralogs to each other in humans. 
In order to analyze methylation activity (mono-, di-, and trimethylation activity), a 
time course experiment and mass spectrometry were utilized to determine if 
MLL1 and WRAD were binding based on methylation data compared to wild-
type MLL1. Each methylation (CH3) results in a 15Da increase. Plotted data did 
indicate a severe loss of dimethylation between MWTWRAD (Fig. 7a, Fig. 7b) and 
MR3765LWRAD (Fig. 8a, Fig. 8b), while there was not a noticeable difference in 
the level of monomethylation. This assay was repeated to validate the correlation 
between mutation and disruption of binding. 
Below are the results from the experiment conducted on August 2, 2012. Figures 
7a (WT) and 8a (R3765L) are the plots from mMass (mono-, di-, tri- from left to 
right), while Figures 7b (WT) and 8b (R3765L) are the same values plotted by 
Microsoft Excel over the time period of 24 hours. 
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Figure 7a 
 
Figure 7b 
 
Figure 8a 
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Figure 8b 
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Once the loss of dimethylation was established when mutating R3765, analytical 
ultracentrifugation was applied to better analyze complex formation. This real 
time optical detection system using UV light absorption is able to distinguish 
molecules based on shape and molecular mass. In wild-type conditions, the MLL1 
and WDR5 complex sediments around 2.80, while separately MLL1 is ~1.80 and 
WDR5 is ~2.37. Data obtained in July 2013 further supported the original 
hypothesis that the MLL1 R3765L mutation negatively effects core complex 
formation and, in doing so, greatly reduces, if not completely eliminates, 
dimethylation. Fig. 9 (MWTWDR5) and 10 (MR3765LWDR5) show the plot from 
SEDFIT (left) and values graphed on Microsoft Excel (right). A minor peak on 
the left exists for both experiments and was attributed to either protein 
degradation or contamination. 
 
Figure 9 
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Figure 10 
MLL1 R3746H – A Neutral Mutation 
Hypothesis: If the R3746H mutation was found in patient screens, but was not 
correlated with KS. Then we therefore hypothesized that it would behave like 
wild-type MLL1. 
To test this hypothesis a similar MALDI-TOF and AUC experimentation set up 
was used to test the similarity of wild-type and R3756H MLL1 proteins. Both of 
which supported the initial hypothesis that was posited. 
Figures 11a (WT) and 12a (R3746H) are peaks from mMass (mono-, di-, 
trimethylation activity from left to right). Figures 11b (WT) and 12b (R3746H) 
are plotted values on Microsoft Excel. Though a small variance exists, the 
methylation trend is very similar. 
 
 
20 
 
 
Figure 11a 
 
Figure 11b 
 
Figure 12a 
21 
 
 
Figure 12b 
Sedimentation experiments agreed with the MALDI-TOF results in that complex 
was forming normally, despite this mutation. Figures 13 (WT) and 14 (R3746H) 
show MLL1-WDR5 complex formation, however experimental data from MLL1 
R3746H was determined to have concentrations that were not stoichiometric. An 
excess of wild-type WDR5 led to the additional peak around 2.24. 
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Figure 13 
 
Figure 14 
 MLL1 R3771T – Presence in PAD2 Citrullination 
Hypothesis: If the arginines at positions MLL1 3765 and 3771 f MLL1 are 
citrullinated by PAD2, then either the R3771 is exposing R3765 to PAD2 or there 
is no significance in this citrullination. Prior experimentation has already 
determined the importance of both the Win motif and MLL1 R3765 in MWRAD 
complex formation
7
. 
Tests had been done before by Valerie Vought with PAD2 after MALDI-TOF 
results showed an arginine 6 residues down from the highly conserved Win motif 
arginine had been citrullinated in both MLL1. In addition, PAD2 displayed a high 
affinity to MLL1 in comparison to the other members of the SET1 family and 
PAD4. 
To determine if PAD2 is a possible model for regulation of MLL1 core complex 
assembly, MLL1 R3771T was tested for disruption of methylation. Figure 15 
lends evidence towards a similarity with wild-type MLL1 methylation behavior.  
23 
 
 
 
Figure 15 
A time course glutathione pulldown assay was created to determine if PAD2 
citrullination negatively impacted core complex formation. Fusion GST-MLL1 
WT and R3771T protein were used to bind with the glutathione beads. 
Optimization tests were conducted to hone down the original conditions. Figure 
19 shows a dramatic decrease in band intensity for WDR5 (top circle) and DPY30 
(bottom circle) over the time period of 90 minutes. The left side being MLL1 WT 
and right side being MLL1 R3771T in complex with WRAD. 
24 
 
 
Figure 19 
Repeat experiments showed similar results, which led to the goal of determining 
if a difference existed between citrullination with and without the arginine at 
position 3771 of MLL1. Due to the faint intensity of bands, analysis was unable to 
draw a conclusive answer. 
Initial steps were taken to utilize western blotting towards offering a better 
method of quantification. Figure 20 shows a successful dot blot of an antibody 
that selectively binds with MWRAD that has been citrullinated by PAD2. Faint 
bands were seen with MWRAD and No CaCl2, which was attributed to 
background binding. Controls of histone H3 (residues 1-20) + PAD2 showed 
slight antibody binding, while the absence of CaCl2 showed no intensity, and the 
enzyme, PAD2, alone did not bind with the antibody. 
25 
 
 
Figure 20 
Unfortunately western blotting results for MLL1 WT and MLL1 R3771T were 
deemed inconclusive. Only two experimental attempts were made during the 
academic school year. The first of which is seen below in Figure 20 (MLL1 WT, 
coomassie) and Figure 21 (MLL1 WT, western blot). The data did show that there 
was an inverse relationship between MLL1 core complex formation from the 
glutathione pulldown and citrulline antibody binding. This supported the 
hypothesis that PAD2 severely decreases complex formation through the 
citrullination of R3765, and R3771 in the process. Both Figure 21 and 22 have the 
same corresponding lanes. Lane 1 is the BioRad Standard Ladder, lane 2 is the 
input, lane 3 through 10 are time points from zero to 1 hour, lane 11 is the WRAD 
control, and lane 12 is the No CaCl2 control. As less complex shows up over time 
on Figure 21, more citrulline antibody binds over time on Figure 22. 
 
26 
 
 
Figure 21 
 
 
Figure 22 
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Chapter IV 
Discussion and Conclusion 
 
 
 
 
 Positive Correlation of MLL1 Mutations and Dimethylation 
MLL1 R3765 was determined to have a significant impact on MLL1 core 
complex formation and normal dimethylation
7
. Results obtained from MALDI-
TOF and AUC were repeated by Stephen Shinsky, a graduate student in Dr. 
Cosgrove’s lab. Unlike other Kabuki Syndrome mutations in MLL2, this arginine 
located in the Win motif led to an almost complete loss of dimethylation. Hence, 
using a paralog of MLL2 R5340, the results supported the initial hypothesis that 
the arginine located at 3765 is crucial in the interaction of MLL1 with WDR5. 
 PeptidylArginine Deiminase 2  
Initial results were not conclusive, but support the hypothesis that MLL1 R3771 
may play a role in citrullination of MLL1 R3765. A flaw exists when the SET1 
family peptides were sent for MALDI-TOF analysis of the 1Da difference of 
arginine and citrulline. MLL1 and MLL4, unlike MLL2, MLL3, SET1a, and 
SET1b included both 3 extra amino acids before and after the central residues. 
This could have aided in the stability of interaction with PAD2 and PAD4. 
28 
 
The arginine located at 3771 is not needed for the interaction of MLL1 with 
WDR5 and is supported by crystal structures that show movement of R3771 
lending further evidence that this amino acid does not interact with the surface of 
WDR5. 
Further research is needed to standardize the testing of SET1 family proteins and 
PAD2/4 either by sending equal length peptide sequences or by using truncated 
constructs in the GST pulldown assay. Shorter intervals of time may help in 
quantifying MLL1 core complex formation. Repeating western blot assays under 
optimized conditions will allow for more accurate quantification of PAD2 
enzymatic activity over time and determine whether the R3771 plays a role in the 
speed of R3765 citrullination. 
 Research Overview and Techniques learned from BCM460 
These past three years of research have been eye opening in teaching me both 
fundamental research techniques and developing a scientific mindset. Much of the 
biochemistry that I learned while in Dr. Cosgrove’s lab has already aided me in 
my undergraduate studies and has helped me obtain interviews for research 
positions after graduation. 
Many thanks go out to the members, both past and present, of the lab. I could not 
have done this without your assistance. Though I wish more data could have been 
collected and better experimental techniques could have been used, I believe 
BCM460 has given me invaluable skills that will continue to be utilized in the 
future. 
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